0000000000429300

AUTHOR

Manisha Chandalia

showing 3 related works from this author

In vivo triglyceride synthesis in subcutaneous adipose tissue of humans correlates with plasma HDL parameters

2016

Backgrounds and aims: Low concentrations of plasma HDL-C are associated with the development of atherosclerotic cardiovascular diseases and type 2 diabetes. Here we aimed to explore the relationship between the in vivo fractional synthesis of triglycerides (fTG) in subcutaneous (s.q.) abdominal adipose tissue (AT), HDL-C concentrations and HDL particle size composition in non-diabetic humans. Methods: The fTG in s.q. abdominal AT was measured in 16 non-diabetic volunteers (7 women, 9 men; Age: 49 ± 20 years; BMI: 31 ± 5 kg/m; Fasting Plasma Glucose: 90 ± 10 mg/dl) after 2H2O labeling. HDL-C concentration and subclasses, large (L-HDL), intermediate (I-HDL) and small (S-HDL) were measured. Re…

Blood GlucoseMale0301 basic medicinemedicine.medical_specialtyAdipocyte; Atheroprotective; Gender-related; HDL-C metabolism; Mass spectrometry; Stable isotope tracer kinetics; Triglycerides; Cardiology and Cardiovascular MedicineAdipose tissueWhite adipose tissueType 2 diabetes030204 cardiovascular system & hematologyTriglycerideArticleAtheroprotective03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInsulin resistanceIn vivoInternal medicineAdipocytemedicineHumansObesityTriglyceridesAgedHDL-C metabolismAdipocyteStable isotope tracer kineticMass spectrometrybusiness.industryLipogenesisCholesterol HDLnutritional and metabolic diseasesMiddle AgedAtherosclerosismedicine.diseaseLipidsObesitySubcutaneous Fat AbdominalGender-related030104 developmental biologyEndocrinologychemistryLipogenesisFemalelipids (amino acids peptides and proteins)Insulin ResistanceCardiology and Cardiovascular MedicinebusinessAtherosclerosis
researchProduct

Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study.

2014

Background Liraglutide, a long-acting glucagon-like peptide-1 (GLP-1) analog, has several non- glycemic properties, but its effect on carotid intima-media thickness (IMT), a recognized marker of subclinical atherosclerosis, is still unknown. Methods A prospective study of 8 months duration in 64 patients with type-2 diabetes and no prior history of coronary artery disease evaluated whether adding liraglutide to metformin affects carotid IMT, measured by color doppler ultrasound. Results After 8 months, fasting glucose decreased by 2.1 mmol/l and HbA1c by 1.9% (p < 0.01 for all). Liraglutide reduced total-cholesterol and triglycerides by 10%, and LDL-cholesterol by 19%, whereas HDL-cholester…

Malemedicine.medical_specialtyEndocrinology Diabetes and MetabolismPilot ProjectsType2 diabetesType 2 diabetesCarotid Intima-Media ThicknessCoronary artery diseaseGlucagon-Like Peptide 1Internal medicineDiabetes mellitusLiraglutide Carotid intima-media thickness Cardiovascular risk Type2 diabetesmedicineHumansHypoglycemic AgentsProspective Studiescardiovascular diseasesProspective cohort studyGlycemicAgedOriginal Investigationbusiness.industryLiraglutideLiraglutideMiddle Agedmedicine.diseaseCardiovascular risk3. Good healthMetforminEndocrinologyIntima-media thicknessDiabetes Mellitus Type 2Cardiologycardiovascular systemFemalebusinessCardiology and Cardiovascular Medicinemedicine.drug
researchProduct

Liraglutide Reduces Oxidative Stress And Restores Heme Oxygenase-1 and Ghrelin Levels in Patients with Type 2 Diabetes: A Prospective Pilot Study

2014

Abstract Context: Liraglutide is a glucagon-like peptide-1 analog and glucose-lowering agent whose effects on cardiovascular risk markers have not been fully elucidated. Objective: We evaluated the effect of liraglutide on markers of oxidative stress, heme oxygenase-1 (HO-1), and plasma ghrelin levels in patients with type-2 diabetes mellitus (T2DM). Design and Setting: A prospective pilot study of 2 months' duration has been performed at the Unit of Diabetes and Cardiovascular Prevention at University of Palermo, Italy. Patients and Intervention(s): Twenty subjects with T2DM (10 men and 10 women; mean age: 57 ± 13 y) were treated with liraglutide sc (0.6 mg/d for 2 wk, followed by 1.2 mg/d…

AdultMalemedicine.medical_specialtyEndocrinology Diabetes and MetabolismClinical Biochemistry030209 endocrinology & metabolismContext (language use)Pilot ProjectsType 2 diabetes030204 cardiovascular system & hematologymedicine.disease_causeBiochemistry03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyGlucagon-Like Peptide 1Internal medicineDiabetes mellitusMedicineHumansHypoglycemic AgentsProspective StudiesAgedbusiness.industryLiraglutideBiochemistry (medical)Liraglutide Heme oxygenase Lipid peroxidation Ghrelin Type-2 diabetesOriginal ArticlesLiraglutideMiddle Agedmedicine.diseaseGhrelinMetformin3. Good healthMetforminOxidative StressEndocrinologychemistryDiabetes Mellitus Type 2GhrelinDrug Therapy CombinationFemaleGlycated hemoglobinbusinessOxidative stressHeme Oxygenase-1medicine.drug
researchProduct